Andrew Reardon, the Chief Legal Officer and Secretary of Ligand Pharmaceuticals, has disclosed several transactions involving the company’s common stock. The filings indicate a combination of stock acquisitions and sales, which are part of his ongoing management activities within the company. This update is significant as it highlights the active trading behavior of executives in the pharmaceutical industry, suggesting a level of confidence in market conditions.
Ligand Pharmaceuticals, identified by its CIK number 0000886163, operates in the pharmaceutical preparations sector. The company is incorporated in Delaware and has its business address at 3911 Sorrento Valley Blvd, Suite 110, San Diego, CA. The company’s fiscal year ends on December 31. Recent filings include a Form 4 dated October 6, 2026, which reports on transactions made as of October 2, 2026.
What the Filing Says
According to the latest filing (accession number 0001950232-26-000003), Reardon executed multiple transactions on October 2, 2026. He acquired 340 shares of common stock through an employee stock option at a price of $52.27 per share. Additionally, he sold 833 shares at a weighted average price of $302.51, 1,976 shares at $303.54, 1,535 shares at $304.52, 404 shares at $306.18, 235 shares at $307.19, and 17 shares at $307.74. Following these transactions, he holds a total of 31,854 shares of the company.
Impact
These transactions may affect stakeholders, including shareholders and potential investors in Ligand Pharmaceuticals. The active trading by Reardon, who holds a significant position within the company, could influence perceptions of the company's stability and future performance. The pharmaceutical industry as a whole remains competitive, with executives frequently engaging in stock transactions as part of their strategic financial management.
What's Next
The filing does not say what happens next.